Summary

Other Scenarios:

Buyer: Dr. Reddy's Laboratories Limited (ADR) (RDY) Last Price: 14.92 Market Cap.: 2.51B
Target: Pharmion Corporation (PHRM) Last Price: 66.23 Market Cap.: 2.47B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 927
Biopharmaceuticals 379
Outsourced Services   68

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 64)
  • Fexofenadine Hydrochloride
  • Amlodipine Besylate
  • Ramipril
  • Carvedilol
Target (Total: 5)
  • Innohep (Tinzaparin Sodium)
  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
  • Vidaza (Azacitidine)
Buyer
  • Biotechnology Division
  • Custom Chemical Services (CCS)
  • Bulk Actives Manufacturing Services
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 2)
  • I-Many, Inc. (IMNY)
  • Intelligroup, Inc. (ITIG)
Target (Total: 6)
  • GPC Biotech AG (ADR) (GPCB)
  • Celgene Corporation (CELG)
  • salesforce.com, inc. (CRM)
  • MethylGene Inc. (MYG:CA)
Buyer (Total: 2)
  • Par Pharmaceutical Companies, Inc. (PRX)
  • SYGNIS Pharma AG
Target (Total: 4)
  • US Oncology, Inc.
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • Government - United Kingdom

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 9,034 417
Revenue Per Employee 138,945.4 647,481.4
Total Revenue 312.0 67.3
Total Expenses 344.2 90.4
Other Revenue 0.0 0.0
Cost of Revenue 159.2 18.2
SG&A Expense 95.2 32.5
Research & Development 22.6 29.1
Other Operating Expense -0.0 0.0
Operating Income -32.2 -23.0
Unusual Income 59.8 8.0
LT Debt to Capital n/a 0
Fwd P/E 16.03 -56.00
Fwd P/Rev 1.96 9.28
Book Value n/a 380.0
Curr Portion of LTD/Cap Lease n/a 0.0

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals

Target

Focused (): Healthcare > Biopharmaceuticals > Oncology

Business Description

Buyer

Dr. Reddy's Laboratories Limited is a global pharmaceutical company with research capabilities. In June 2006, The Company launched simvastatin and finasteride, the generic versions of Zocor and Proscar respectively, as authorized generic products of Merck. It has seven molecules or New Chemical Entities (NCEs), as on March 31, 2007, of which five are in clinical development and two at pre-clinical stages. The Company has completed construction of a facility at APIIC Special Economic Zone (SEZ) at Visakhapatnam, Andhra Pradesh for manufacture of oral and injectible cytotoxic finished dosages. The Company has six segments: Formulations, Active Pharmaceutical Ingredients and Intermediates (API), Generics, Critical Care and Biotechnology, Drug Discovery and Custom Pharmaceutical Services (CPS). In September 2007, the United States Food and Drug Administration (FDA) granted final approval for its abbreviated new drug application (ANDA) for Ranitidine (Zantac) 150-milligram tablet.

Target

Pharmion Corporation (Pharmion) is a global pharmaceutical company that acquires, develops and commercializes products for the treatment of hematology and oncology patients. It has established a portfolio of approved products and product candidates focused on the hematology and oncology markets. These include Pharmion?s primary commercial products, Vidaza (azacitidine for injection), which it markets and sells as an approved treatment for myelodysplastic syndromes in the United States, Switzerland, Israel and the Philippines. and Thalidomide Pharmion 50 milligram, a therapy for the treatment of multiple myeloma and certain other forms of cancer, which it sells on a compassionate use or named patient basis in certain countries of Europe. Thalidomide Pharmion is approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma after the failure of standard therapies. In November 2006, it acquired Cabrellis Pharmaceuticals Corporation.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 54 72.65
Operating Margin % 10.52 -40.39
Quick Ratio n/a 4.49
Current Ratio n/a 4.89
Coverage Ratio -0 -0.08
Total Assets n/a 451.5
Return on Equity % n/a -26.47
Return on Assets % n/a -22.28
Cash+ ST Inv. Per Share n/a 6.96
Total Debt 0.0 0.0
Total Debt to Equity % n/a 0
Total Debt to Tangible Equity % n/a 0
Debt to Asset % n/a 0.00

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Outsourced Services  
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Allergies  
Upper Respiratory  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Fexofenadine Hydrochloride
  
Cardiovascular System
Heart Disorders  
Angina  
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.

Buyer Products:

  • Amlodipine Besylate
  
Heart Failure (HF)  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.

Buyer Products:

  • Ramipril
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Carvedilol
  
Myocardial Infarction (MI)  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Carvedilol
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.

Buyer Products:

  • Pravastatin Sodium
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • RUS 3108
  
Vascular Disorders
Atherosclerosis  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.

Buyer Products:

  • Pravastatin Sodium
  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat the narrowing or hardening of the arteries by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.

Buyer Products:

  • Clopidogrel Bisulfate
  
Coronary Artery Disease (CAD)  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by preventing the synthesis of cholesterol.

Buyer Products:

  • Simvastatin
  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Hypertension  
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.

Buyer Products:

  • Doxazosin
  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.

Buyer Products:

  • Enalaprilat
  • Ramipril
  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Enalapril Maleate/Hydrochlorothiazide
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Carvedilol
  
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Amlodipine Besylate
  
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Dermatology  
Hair Disorders  
Alopecia (Hair Loss)  
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.

Buyer Products:

  • Finasteride
  
Lesion/Scaling Disorders  
Actinic Keratoses  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat actinic keratoses by blocking cyclooxygenase activity.

Buyer Products:

  • Diclofenac Sodium Delayed Release
  
Chronic Urticaria  
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.

Buyer Products:

  • Fexofenadine Hydrochloride
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroduodenal Disorders  
Peptic Ulcers  
Duodenal  
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Nizatidine
  • Famotidine
  • Ranitidine
  
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Omeprazole Omeprazole Delayed Release
  • Rabeprazole Sodium Delayed Release
  
Gastric  
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Famotidine
  • Ranitidine
  • Nizatidine
  
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Omeprazole Omeprazole Delayed Release
  • Rabeprazole Sodium Delayed Release
  
Zollinger-Ellison Syndrome  
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Ranitidine
  • Famotidine
  
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Rabeprazole Sodium Delayed Release
  • Pantoprazole Sodium Extended Release
  • Omeprazole Omeprazole Delayed Release
  
Gastroesophageal Disorders  
Acid Indigestion/Heartburn  
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.

Buyer Products:

  • Ranitidine
  • Nizatidine
  • Famotidine OTC
  • Famotidine
  
Proton Pump Inhibitors
Therapeutics that treat heartburn by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Omeprazole Omeprazole Delayed Release
  • Pantoprazole Sodium Extended Release
  • Omeprazole Delayed-Release Capsules
  
Erosive Esophagitis  
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Nizatidine
  • Ranitidine
  
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Omeprazole Omeprazole Delayed Release
  • Pantoprazole Sodium Extended Release
  
Gastroesophageal Reflux Disease (GERD)  
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Famotidine
  • Ranitidine
  • Nizatidine
  
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Omeprazole Omeprazole Delayed Release
  • Pantoprazole Sodium Extended Release
  • Rabeprazole Sodium Delayed Release
  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.

Buyer Products:

  • Ondansetron Hydrochloride
  
Endocrinology/Metabolism  
Diabetes  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.

Buyer Products:

  • Metformin Hydrochloride
  
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.

Buyer Products:

  • Glimepiride
  
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitize organs to insulin.

Buyer Products:

  • Balaglitazone (DRF2593-307)
  • Rosiglitazone Maleate
  
Intermediary Metabolism Disorders  
Hypercholesterolemia  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Pravastatin Sodium
  • Simvastatin
  
Hyperlipidemia  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Simvastatin
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • DRF 11605
  • DRF-10945
  
Hematology
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • DRF-10945

Target Products:

  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
Serum Factor Disorders  
Hypercholesterolemia  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Simvastatin
  • Pravastatin Sodium
  
Hyperlipidemia  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Simvastatin
  
White Blood Cell (WBC) Disorders  
Myelodysplastic Syndromes (MDS)  
Antimetabolite Agents  
Pyrimidine Analogs
Therapeutics that treat and manage rmyelodysplastic syndrome by interfering with the production of DNA.

Target Products:

  • Vidaza (Azacitidine)
  
Immunology  
Autoimmune Disorders  
Arthritis  
Rheumatoid Arthritis (RA)  
Analgesics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.

Buyer Products:

  • Meloxicam
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.

Buyer Products:

  • Diclofenac Sodium Delayed Release
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • DRF-4848 (Specific COX-2 Inhibitor)
  
Infectious Diseases  
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ofloxacin
  • Moxifloxacin
  • Ciprofloxacin Extended-Release
  • Ciprofloxacin
  • Levofloxacin
  
Narrow Spectrum  
Digestive System  
Heliobacter pylori  
Proton Pump Inhibitors
Therapeutics treat digestive infections caused by Helicobacter pylori bacteria by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Rabeprazole Sodium Delayed Release
  
Respiratory System  
Bronchitis  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting an enzyme vital to bacterial DNA transcription and repair.

Buyer Products:

  • Ofloxacin
  
Pneumonia  
Quinolones/Fluoroquinolones
Therapeutics that treat inflammation of the lungs caused by bacterial infection by bacterial infection by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  • Ciprofloxacin Extended-Release
  
Respiratory Tract Infections  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin Extended-Release
  • Ciprofloxacin
  • Ofloxacin
  
Urology  
Prostatitis  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ciprofloxacin
  • Ofloxacin
  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Ofloxacin
  • Ciprofloxacin Extended-Release
  • Ciprofloxacin
  
Mycological (Fungal)  
Antifungal Agents  
Broad Spectrum  
Amine Derivatives  
Allyl
Therapeutics that treat fungal infections by causing a deficiency in the cell wall.

Buyer Products:

  • Terbinafine Hydrochloride
  
Narrow Spectrum  
Nervous System  
Cryptococcal Meningitis  
Triazoles
Therapeutics that treat fungal infections of lining of the brain and the spinal cord by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Fluconazole
  
Otolaryngology (Ear/Nose/Throat)  
Esophageal Candidiasis  
Triazoles
Therapeutics that treat fungal infections of the esophagus caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Fluconazole
  
Oropharyngeal Candidiasis  
Azoles  
Triazoles
Therapeutics that treat fungal infections of the mouth and pahrynx caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Fluconazole
  
Urology  
Vaginal Candidiasis  
Azoles  
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Fluconazole
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • DRL 13792
  • DRF-3188
  
Musculoskeletal System  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.

Buyer Products:

  • Raloxifene
  
Joint Disorders  
Osteoarthritis (OA)  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.

Buyer Products:

  • Meloxicam
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Oxaprozin
  
Rheumatoid Arthritis (RA)  
Analgesics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.

Buyer Products:

  • Meloxicam
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.

Buyer Products:

  • Oxaprozin
  
Neurology  
Neurological Disorders  
Alzheimer`s Disease  
Acetylcholinesterase Inhibitors
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine.

Buyer Products:

  • Rivastigmine Tartrate
  
Epilepsy  
Partial Seizures  
Complex  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.

Buyer Products:

  • Levetiracetam
  
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.

Buyer Products:

  • Lamotrigine Tablets/Chewable Tablets
  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Buyer Products:

  • Zonisamide
  
Monotherapy  
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.

Buyer Products:

  • Lamotrigine Tablets/Chewable Tablets
  
Simple  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Buyer Products:

  • Zonisamide
  
Monotherapy  
Sodium Channel Blocking Agents
Therapeutics that treat simple partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses.

Buyer Products:

  • Lamotrigine Tablets/Chewable Tablets
  
Headaches  
Vascular (Migraine)  
Acute Treatments  
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.

Buyer Products:

  • Sumatriptan Succinate
  
Spasticity (Spinal Shock)  
Alpha Adrenergic Receptor Agonists
Therapeutics that treat spasticity by stimulating the alpha adrenergic receptors.

Buyer Products:

  • Tizanidine Hydrochloride
  
Psychiatric Disorders  
Anxiety  
Generalized Anxiety Disorder (GAD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.

Buyer Products:

  • Escitalopram Oxalate
  
Obsessive Compulsive Disorder (OCD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.

Buyer Products:

  • Sertraline Hydrochloride
  • Fluoxetine Hydrochloride
  
Panic Disorder  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.

Buyer Products:

  • Sertraline Hydrochloride
  
Post-Traumatic Stress Disorder (PTSD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.

Buyer Products:

  • Sertraline Hydrochloride
  
Social Anxiety Disorder (SAD)  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.

Buyer Products:

  • Sertraline Hydrochloride
  
Eating Disorders  
Bulimia  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.

Buyer Products:

  • Fluoxetine Hydrochloride
  
Mood Disorders  
Bipolar Disorders (Manic Depressive Disorders)  
Monoaminergic Antagonists
Therapeutics that treat bipolar disorder by blocking the serotonin and dopamine receptors.

Buyer Products:

  • Risperidone
  
Depression  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.

Buyer Products:

  • Sertraline Hydrochloride
  • Fluoxetine Hydrochloride
  • Escitalopram Oxalate
  • Citalopram Hydrobromide
  
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat depression by inhibiting the neuronal uptake of serotonin and norepinephrine.

Buyer Products:

  • Nefazodone HCL tablets
  
Premenstrual Dysphoric Disorders  
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.

Buyer Products:

  • Fluoxetine Hydrochloride
  • Sertraline Hydrochloride
  
Schizophrenia  
Monoaminergic Antagonists
Therapeutics that treat schizophrenia by blocking the serotonin and dopamine receptors.

Buyer Products:

  • Olanzapine
  • Risperidone
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Buyer Products:

  • Zolpidem Tartrate
  
Oncology
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • DRF-1042

Target Products:

  • Oral Azacitidine
  • Vidaza (Azacitidine)
  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • DRF-3188
  
Respiratory System/Thoracic  
Lung Cancer  
Small Cell Lung Cancer (SCLC)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.

Target Products:

  • Amrubicin (Anthracycline)
  
Pain Management  
Non-Narcotics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.

Buyer Products:

  • Meloxicam
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Ketorolac
  • Naproxen sodium
  • Ibuprofen
  
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Decongestants
Therapeutic combinations that produce insensibility or numbness through the inhibition of prostoglandins while also preventing nasal decongestion.

Buyer Products:

  • Naproxen Sodium/Pseudoephedrine HCI Extended Release Tablets
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.

Buyer Products:

  • DRF-4848 (Specific COX-2 Inhibitor)
  
Respiratory System  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Fexofenadine Hydrochloride
  
Antitussives
Therapeutics that relieve or prevent coughs.

Buyer Products:

  • Dextromethorphan
  
Surgery
General  
Complications  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.

Buyer Products:

  • Ondansetron Hydrochloride
  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Target Products:

  • Innohep (Tinzaparin Sodium)
  
Urology  
Male Genital Disorders  
Prostate  
Benign Prostate Hyperplasia (BPH)  
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.

Buyer Products:

  • Doxazosin
  
Outsourced Services  
Development/Manufacturing Services  
Chemistry Services
Outsourced companies that provide medicinal chemistry, organic synthesis, process research, cGMP synthesis, and analytical services to the biopharmaceutical industry.

Buyer Products:

  • Biotechnology Division
  
Contract Manufacturing Organizations (CMO)  
Pharmaceuticals  
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.

Buyer Products:

  • Custom Chemical Services (CCS)
  • Bulk Actives Manufacturing Services
  
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.

Buyer Products:

  • Biotechnology Division
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  GlaxoSmithKline plc (ADR) n/a 129,213.735 12.21 12.17 2.87 2.89 12.60
sanofi-aventis (ADR) n/a 109,679.174 18.58 11.12 2.51 2.86 n/a
Eli Lilly & Co. n/a 57,555.042 25.80 14.54 3.25 3.18 5.48
Buyer
  Roche Holding Ltd. (ADR) n/a 152,328.536 19.21 18.12 3.77 3.89 5.64
GlaxoSmithKline plc (ADR) n/a 129,213.735 12.21 12.17 2.87 2.89 12.60
Novartis AG (ADR) n/a 115,310.846 13.94 14.29 3.03 2.95 4.04
sanofi-aventis (ADR) n/a 109,679.174 18.58 11.12 2.51 2.86 n/a
Bayer AG (ADR) n/a 60,061.987 8.29 15.86 1.31 1.43 n/a
Eli Lilly & Co. n/a 57,555.042 25.80 14.54 3.25 3.18 5.48
Teva Pharmaceutical Industries Ltd (ADR) n/a 33,753.520 18.33 19.29 3.71 3.71 12.51
Cardinal Health, Inc. n/a 20,399.391 10.40 14.32 0.23 0.22 16.38
Koninklijke DSM N.V. (ADR) n/a 7,062.480 12.16 9.38 0.54 n/a 1.10
Barr Pharmaceuticals, Inc. n/a 5,568.546 0.00 17.44 2.30 2.25 n/a
Mylan Inc. n/a 3,626.351 12.35 12.28 1.90 1.40 3.87
Target
  Pfizer Inc. n/a 154,421.887 18.62 9.64 3.18 3.31 n/a
GlaxoSmithKline plc (ADR) n/a 129,213.735 12.21 12.17 2.87 2.89 12.60
sanofi-aventis (ADR) n/a 109,679.174 18.58 11.12 2.51 2.86 n/a
Genentech, Inc. n/a 71,389.037 25.77 21.93 6.09 5.57 n/a
Eli Lilly & Co. n/a 57,555.042 25.80 14.54 3.25 3.18 5.48
Celgene Corporation n/a 19,860.224 114.12 52.62 15.69 14.58 8.48
Millennium Pharmaceuticals, Inc. n/a 4,730.028 0.00 122.08 9.72 9.50 7.38
MGi Pharma, Inc. n/a 3,304.322 0.00 117.14 8.95 8.04 173.86
SuperGen, Inc. n/a 201.748 124.75 17.65 11.18 8.94 2.30
Poniard Pharmaceuticals, Inc. n/a 179.181 0.00 -4.90 n/a 5.60 2.07
Vion Pharmaceuticals, Inc. n/a 38.882 0.00 -0.96 1,914.50 1,849.70 4.71

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  I-Many, Inc. n/a 156.768 0.00 -15.26 4.28 3.78 n/a
Intelligroup, Inc. n/a 92.436 0.00 n/a 0.67 n/a 3.13
Target
  GPC Biotech AG (ADR) 66.00% 114.028 0.00 n/a 3.65 n/a 1.51
Celgene Corporation n/a 19,860.224 114.12 52.62 15.69 14.58 8.48
salesforce.com, inc. n/a 6,252.214 543.86 403.21 9.25 9.00 16.95
MethylGene Inc. n/a 100.877 0.00 n/a 6.94 n/a 2.02
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Par Pharmaceutical Companies, Inc. n/a 661.696 13.07 13.06 0.83 0.86 1.75
SYGNIS Pharma AG n/a n/a n/a n/a n/a n/a n/a
Target
  US Oncology, Inc. 19.00% n/a n/a n/a n/a n/a n/a
Cardinal Health, Inc. 11.00% 20,399.391 10.40 14.32 0.23 0.22 16.38
McKesson Corporation 9.00% 17,478.994 17.80 18.69 0.18 0.18 5.56
Government - United Kingdom n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Par Pharmaceutical Companies, Inc. n/a 661.696 13.07 13.06 0.83 0.86 1.75
I-Many, Inc. n/a 156.768 0.00 -15.26 4.28 3.78 n/a
SCOLR Pharma Inc. n/a 45.409 0.00 n/a 17.55 n/a 4.05
Immtech Pharmaceuticals, Inc. n/a 43.550 0.00 n/a 11.64 n/a 4.29
Pharmascience Inc. n/a n/a n/a n/a n/a n/a n/a
Argenta Discovery Ltd. n/a n/a n/a n/a n/a n/a n/a
Target
  Pfizer Inc. n/a 154,421.887 18.62 9.64 3.18 3.31 n/a
Cardinal Health, Inc. n/a 20,399.391 10.40 14.32 0.23 0.22 16.38
Celgene Corporation n/a 19,860.224 114.12 52.62 15.69 14.58 8.48
McKesson Corporation n/a 17,478.994 17.80 18.69 0.18 0.18 5.56
MGi Pharma, Inc. n/a 3,304.322 0.00 117.14 8.95 8.04 173.86
GPC Biotech AG (ADR) n/a 114.028 0.00 n/a 3.65 n/a 1.51
MethylGene Inc. n/a 100.877 0.00 n/a 6.94 n/a 2.02
Dainippon Sumitomo Pharma Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
US Oncology, Inc. n/a n/a n/a n/a n/a n/a n/a
LEO Pharma A/S n/a n/a n/a n/a n/a n/a n/a
Nippon Shinyaku Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 1,331.7 255.9 1,587.6
Other Revenue 0.0 0.0 0.0
Total Revenue 1,331.7 255.9 1,587.6
Cost of Revenue 612.6 70.0 682.6
SG&A Expense 369.4 125.2 494.6
Depreciation & Amortization 40.3 9.9 50.1
Research & Development 85.1 91.9 177.1
Interest Expense -21.1 0.0 -21.1
Other Operating Expense 0.6 0.0 0.6
Unusual Expense (Income) 104.6 62.3 166.9
Total Expenses 1,191.6 359.2 1,550.8
Operating Income 140.1 -103.3 36.7
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -0.3 8.1 7.8
Other, Net 4.9 0.0 4.9
Income Before Taxes 144.6 -95.3 49.4
Income Taxes -30.1 5.3 -24.7
Income After Taxes 174.7 -100.6 74.1
Minority Interest (IS) 0.1 0.0 0.1
Net Income - Excl. Xord. Items 174.8 -100.6 74.2
Net Income - Incl. Xord. Items 174.8 -100.6 74.2
Income Avail. to Common 174.8 -100.6 74.2
Share Items
Basic Avg. Shares Outstanding 168.1 37.0 205.1
Basic EPS - Excl. Xord. Items 1.04 n/a 0.36
Basic EPS - Incl. Xord. Items 1.04 n/a 0.36
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 168.1 37.0 205.1
F.D. EPS - Excl. Xord. Items 1.04 n/a 0.36
F.D. EPS - Incl. Xord. Items 1.04 n/a 0.36
Dividends Per Common Share 0.09 0.00 0.09
Balance Sheet
Assets
Cash and Equivalents n/a 135.0 135.0
ST Investments n/a 122.6 122.6
Accounts Receivable n/a 45.4 45.4
Inventory n/a 13.0 13.0
Other Current Assets n/a 14.0 14.0
Current Assets n/a 330.0 330.0
Accum D&A n/a 0.0 0.0
PPE, Net n/a 11.0 11.0
Goodwill & Intangibles n/a 104.7 104.7
Other Assets n/a 0.0 0.0
Other LT Assets n/a 5.8 5.8
Total Assets n/a 451.5 451.5
Liabilities
Accounts Payable n/a 10.1 10.1
Payable/Accrued n/a 0.0 0.0
Accrued Expenses n/a 57.5 57.5
ST Debt n/a 0.0 0.0
Other (Current) Liabilities n/a 0.0 0.0
Current Liab. n/a 67.5 67.5
LT Debt n/a 0.0 0.0
Total LT Debt n/a 0.0 0.0
Deferred Taxes n/a 3.0 3.0
Other LT Liab. n/a 1.0 1.0
Total Liabilities n/a 71.5 71.5
Shareholders Equity
Common Stock n/a 0.0 0.0
Additional Paid in Capital n/a 627.5 627.5
Retained Earnings n/a -263.2 -263.2
Other Equity n/a 15.7 15.7
Total Equity n/a 380.0 380.0
Total Liab. & Equity n/a 451.5 451.5
Shares Outstanding n/a 37.2 37.2
Cash Flow
Operating Cash Flow
CF Net Income n/a -100.6 -100.6
CF Depreciation n/a 12.4 12.4
CF Deferred Taxes n/a 0.0 0.0
Other Non-Cash Items n/a 3.4 3.4
Change in Working Capital n/a 20.2 20.2
Total Cash From Operating Activities n/a -64.7 -64.7
Investing Cash Flow (not calculated)
Capital Expenditures n/a -6.7 -6.7
Other Investing Cash Flows n/a -32.1 -32.1
Total Cash From Investing Activities n/a -38.8 -38.8
Financing Cash Flow (not calculated)
Dividends Paid n/a 0.0 0.0
Purchase Or Sale of Stock n/a 6.1 6.1
Purchase and Retirement of Debt n/a -0.9 -0.9
Other Financing Cash Flow n/a 130.8 130.8
Total Cash From Financing Activities n/a 135.9 135.9
Exchange Rate Effects n/a 3.8 3.8
Net Change in Cash n/a 36.2 36.2
Cash Taxes Paid n/a 11.4 11.4
Cash Interest Paid n/a 0.4 0.4